The early clinical signals for APR-1051 are encouraging, but remain unconfirmed and in a small patient cohort. Traders should monitor the Q2 2026 data update for further validation. The capital raise reduces near-term dilution risk, but the pause of ATRN-119 represents a strategic setback. Any future partnership or combination trial announcements could serve as catalysts.
Price Chart
Executive Summary
Aprea Therapeutics reported Q4 and full-year 2025 financial results, highlighted by early clinical proof-of-concept for its WEE1 inhibitor APR-1051 in endometrial cancer, with two unconfirmed partial responses. The company reduced operating losses year-over-year and raised $8.7 million in private placements, extending its cash runway into Q1 2027. However, R&D spending declined due to a paused ATR inhibitor program.
Key Financial Metrics
Key Facts
- Two unconfirmed partial responses (uPR) observed in endometrial cancer patients with PPP2R1A mutation treated with APR-1051 at 150 mg and 220 mg doses, with 50% tumor reduction and significant CA-125 declines.
- Company raised $3.1 million in December 2025 and $5.6 million in January 2026 via private placements, totaling $8.7 million in gross proceeds.
- Cash and cash equivalents were $14.6 million as of December 31, 2025, down from $22.8 million a year prior; runway now extends into Q1 2027.
- Q4 2025 operating loss was $2.6 million vs. $3.2 million in Q4 2024; full-year 2025 operating loss was $13.2 million vs. $14.3 million in 2024.
- R&D expenses dropped to $1.0 million in Q4 2025 from $2.4 million in Q4 2024, primarily due to reduced trial activity and the pause of the ABOYA-119 trial in October 2025.
- Net loss was $2.5 million ($0.32/share) in Q4 2025 vs. $2.9 million ($0.49/share) in Q4 2024.
- ATRN-119 clinical program has been paused; company is exploring combination therapies with radiation and immuno-oncology agents.
Financial Impact
Reduced net loss by $0.44 million YoY in Q4 and $0.36 million for the full year, while raising $8.7 million in new capital. R&D spending cut by 57% YoY in Q4.
Risk Factors
- Clinical responses are unconfirmed and based on only two patients; may not be durable or reproducible.
- ATRN-119 program is paused with no clear path forward, representing pipeline risk.
- Market cap is extremely low ($8M), indicating high risk and potential illiquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers